Skip to Main Content

While investors may have cheered the recent $74 billion bid that Bristol-Myers Squibb (BMY) made for Celgene (CELG), a pair of Congressional lawmakers want federal authorities to examine the extent to which such a deal may impede competition or cause higher drug prices for Americans.

In a letter sent last Friday to the Federal Trade Commission and the Department of Justice, Rep. Peter Welch (D-Vt.) and Rep. Francis Rooney (R-Fla.) expressed concern that the takeover could reduce treatment options for patients by giving Bristol-Myers access to product lines that may either compete with or complement its current portfolio of cancer drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • The fact that I can make a comment on this article for free, but have to pay to read it, means that anyone can make a biased, untrue, crazy opinionated comment to try to sway whoever is reading. Nice job website design team. I’ll sell you my advice so I can read the article for free.

Comments are closed.